Argenx SE Surges with $790M in Q1 2025 Sales, Analysts Upgrade to Buy

Argenx SE, a prominent biotech company, has emerged as one of the most profitable investments in the sector. In the first quarter of 2025, the company reported global product net sales of $790 million, inclusive of both its VYVGART and VYVGART SC treatments. This represents a remarkable 99% year-over-year growth compared to Q1 2024, as well as a 7% increase from the previous quarter.

The company's strong performance has caught the attention of analysts, with Deutsche Bank upgrading Argenx SE to Buy from Hold and setting a price target of €550. This positive outlook is driven by Argenx SE's robust underlying fundamentals, including impressive patient and prescriber metrics, which have fueled the company's continued growth in the autoimmune disease treatment market.

Argenx SE operates through four key segments: the United States, Japan, EMEA, and China, demonstrating its global reach and diversified revenue streams. As the company continues to innovate and expand its product portfolio, it is poised to maintain its position as a leading player in the biotech industry.